Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2009

Open Access 01-12-2009 | Research article

Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions

Authors: Trinidad Garcia-Iglesias, Alicia del Toro-Arreola, Benibelks Albarran-Somoza, Susana del Toro-Arreola, Pedro E Sanchez-Hernandez, Maria Guadalupe Ramirez-Dueñas, Luz Ma. Adriana Balderas-Peña, Alejandro Bravo-Cuellar, Pablo C Ortiz-Lazareno, Adrian Daneri-Navarro

Published in: BMC Cancer | Issue 1/2009

Login to get access

Abstract

Background

Persistent high risk HPV infection can lead to cervical cancer, the second most common malignant tumor in women worldwide. NK cells play a crucial role against tumors and virus-infected cells through a fine balance between activating and inhibitory receptors. Expression of triggering receptors NKp30, NKp44, NKp46 and NKG2D on NK cells correlates with cytolytic activity against tumor cells, but these receptors have not been studied in cervical cancer and precursor lesions. The aim of the present work was to study NKp30, NKp46, NKG2D, NKp80 and 2B4 expression in NK cells from patients with cervical cancer and precursor lesions, in the context of HPV infection.

Methods

NKp30, NKp46, NKG2D, NKp80 and 2B4 expression was analyzed by flow cytometry on NK cells from 59 patients with cervical cancer and squamous intraepithelial lesions. NK cell cytotoxicity was evaluated in a 4 hour CFSE/7-AAD flow cytometry assay. HPV types were identified by PCR assays.

Results

We report here for the first time that NK cell-activating receptors NKp30 and NKp46 are significantly down-regulated in cervical cancer and high grade squamous intraepithelial lesion (HGSIL) patients. NCRs down-regulation correlated with low cytolytic activity, HPV-16 infection and clinical stage. NKG2D was also down-regulated in cervical cancer patients.

Conclusion

Our results suggest that NKp30, NKp46 and NKG2D down-regulation represent an evasion mechanism associated to low NK cell activity, HPV-16 infection and cervical cancer progression.
Appendix
Available only for authorised users
Literature
1.
2.
Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S: Human papillomavirus and cervical cancer. Lancet. 2007, 370 (9590): 890-907. 10.1016/S0140-6736(07)61416-0.CrossRefPubMed
3.
Kobayashi A, Greenblatt RM, Anastos K, Minkoff H, Massad LS, Young M, Levine AM, Darragh TM, Weinberg V, Smith-McCune KK: Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res. 2004, 64 (18): 6766-6774. 10.1158/0008-5472.CAN-04-1091.CrossRefPubMed
4.
Frazer I: Correlating immunity with protection for HPV infection. Int J Infect Dis. 2007, 11 (Suppl 2): S10-16. 10.1016/S1201-9712(07)60016-2.CrossRefPubMed
5.
Stanley M: Immunobiology of HPV and HPV vaccines. Gynecol Oncol. 2008, 109 (2 Suppl): S15-21. 10.1016/j.ygyno.2008.02.003.CrossRefPubMed
6.
Peng S, Trimble C, Wu L, Pardoll D, Roden R, Hung CF, Wu TC: HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions. Clin Cancer Res. 2007, 13 (8): 2479-2487. 10.1158/1078-0432.CCR-06-2916.CrossRefPubMedPubMedCentral
7.
Dillon S, Sasagawa T, Crawford A, Prestidge J, Inder MK, Jerram J, Mercer AA, Hibma M: Resolution of cervical dysplasia is associated with T-cell proliferative responses to human papillomavirus type 16 E2. J Gen Virol. 2007, 88 (Pt 3): 803-813. 10.1099/vir.0.82678-0.CrossRefPubMed
8.
Wira CR, Fahey JV, Sentman CL, Pioli PA, Shen L: Innate and adaptive immunity in female genital tract: cellular responses and interactions. Immunol Rev. 2005, 206: 306-335. 10.1111/j.0105-2896.2005.00287.x.CrossRefPubMed
9.
Manickam A, Sivanandham M, Tourkova IL: Immunological role of dendritic cells in cervical cancer. Adv Exp Med Biol. 2007, 601: 155-162.CrossRefPubMed
10.
Hasan UA, Bates E, Takeshita F, Biliato A, Accardi R, Bouvard V, Mansour M, Vincent I, Gissmann L, Iftner T, et al: TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol. 2007, 178 (5): 3186-3197.CrossRefPubMed
11.
McKenzie J, King A, Hare J, Fulford T, Wilson B, Stanley M: Immunocytochemical characterization of large granular lymphocytes in normal cervix and HPV associated disease. J Pathol. 1991, 165 (1): 75-80. 10.1002/path.1711650112.CrossRefPubMed
12.
13.
Waldhauer I, Steinle A: NK cells and cancer immunosurveillance. Oncogene. 2008, 27 (45): 5932-5943. 10.1038/onc.2008.267.CrossRefPubMed
14.
Moretta L, Bottino C, Pende D, Castriconi R, Mingari MC, Moretta A: Surface NK receptors and their ligands on tumor cells. Semin Immunol. 2006, 18 (3): 151-158. 10.1016/j.smim.2006.03.002.CrossRefPubMed
15.
Textor S, Durst M, Jansen L, Accardi R, Tommasino M, Trunk MJ, Porgador A, Watzl C, Gissmann L, Cerwenka A: Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. Int J Cancer. 2008, 123 (10): 2343-2353. 10.1002/ijc.23733.CrossRefPubMed
16.
Lecoeur H, Fevrier M, Garcia S, Riviere Y, Gougeon ML: A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity. J Immunol Methods. 2001, 253 (1–2): 177-187. 10.1016/S0022-1759(01)00359-3.CrossRefPubMed
17.
Bui JD, Schreiber RD: Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?. Curr Opin Immunol. 2007, 19 (2): 203-208. 10.1016/j.coi.2007.02.001.CrossRefPubMed
18.
Strowig T, Brilot F, Munz C: Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity. J Immunol. 2008, 180 (12): 7785-7791.CrossRefPubMedPubMedCentral
19.
Bottley G, Watherston OG, Hiew YL, Norrild B, Cook GP, Blair GE: High-risk human papillomavirus E7 expression reduces cell-surface MHC class I molecules and increases susceptibility to natural killer cells. Oncogene. 2008, 27 (12): 1794-1799. 10.1038/sj.onc.1210798.CrossRefPubMed
20.
Fauriat C, Just-Landi S, Mallet F, Arnoulet C, Sainty D, Olive D, Costello RT: Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood. 2007, 109 (1): 323-330. 10.1182/blood-2005-08-027979.CrossRefPubMed
21.
Epling-Burnette PK, Bai F, Painter JS, Rollison DE, Salih HR, Krusch M, Zou J, Ku E, Zhong B, Boulware D, et al: Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood. 2007, 109 (11): 4816-4824. 10.1182/blood-2006-07-035519.CrossRefPubMedPubMedCentral
22.
Sivori S, Pende D, Bottino C, Marcenaro E, Pessino A, Biassoni R, Moretta L, Moretta A: NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur J Immunol. 1999, 29 (5): 1656-1666. 10.1002/(SICI)1521-4141(199905)29:05<1656::AID-IMMU1656>3.0.CO;2-1.CrossRefPubMed
23.
Byrd A, Hoffmann SC, Jarahian M, Momburg F, Watzl C: Expression analysis of the ligands for the Natural Killer cell receptors NKp30 and NKp44. PLoS ONE. 2007, 2 (12): e1339-10.1371/journal.pone.0001339.CrossRefPubMedPubMedCentral
24.
Arreygue-Garcia NA, Daneri-Navarro A, del Toro-Arreola A, Cid-Arregui A, Gonzalez-Ramella O, Jave-Suarez LF, Aguilar-Lemarroy A, Troyo-Sanroman R, Bravo-Cuellar A, Delgado-Rizo V, et al: Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer. 2008, 8: 16-10.1186/1471-2407-8-16.CrossRefPubMedPubMedCentral
25.
Li H, Han Y, Guo Q, Zhang M, Cao X: Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta1. J Immunol. 2009, 182 (1): 240-249.CrossRefPubMed
26.
Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L: Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood. 2008, 111 (3): 1327-1333. 10.1182/blood-2007-02-074997.CrossRefPubMed
27.
Vitale C, Chiossone L, Cantoni C, Morreale G, Cottalasso F, Moretti S, Pistorio A, Haupt R, Lanino E, Dini G, et al: The corticosteroid-induced inhibitory effect on NK cell function reflects down-regulation and/or dysfunction of triggering receptors involved in natural cytotoxicity. Eur J Immunol. 2004, 34 (11): 3028-3038. 10.1002/eji.200425418.CrossRefPubMed
28.
Hao S, Zhao J, Zhou J, Zhao S, Hu Y, Hou Y: Modulation of 17beta-estradiol on the number and cytotoxicity of NK cells in vivo related to MCM and activating receptors. Int Immunopharmacol. 2007, 7 (13): 1765-1775. 10.1016/j.intimp.2007.09.017.CrossRefPubMed
29.
Romero AI, Thoren FB, Brune M, Hellstrand K: NKp46 and NKG2D receptor expression in NK cells with CD56dim and CD56bright phenotype: regulation by histamine and reactive oxygen species. Br J Haematol. 2006, 132 (1): 91-98. 10.1111/j.1365-2141.2005.05842.x.CrossRefPubMed
30.
Lee JC, Lee KM, Kim DW, Heo DS: Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol. 2004, 172 (12): 7335-7340.CrossRefPubMed
31.
Baritaki S, Sifakis S, Huerta-Yepez S, Neonakis IK, Soufla G, Bonavida B, Spandidos DA: Overexpression of VEGF and TGF-beta1 mRNA in Pap smears correlates with progression of cervical intraepithelial neoplasia to cancer: implication of YY1 in cervical tumorigenesis and HPV infection. Int J Oncol. 2007, 31 (1): 69-79.PubMed
32.
Hagemann T, Bozanovic T, Hooper S, Ljubic A, Slettenaar VI, Wilson JL, Singh N, Gayther SA, Shepherd JH, Van Trappen PO: Molecular profiling of cervical cancer progression. Br J Cancer. 2007, 96 (2): 321-328. 10.1038/sj.bjc.6603543.CrossRefPubMedPubMedCentral
33.
Sedlmayr P, Semlitsch M, Gebru G, Karpf E, Reich O, Tang T, Wintersteiger R, Takikawa O, Dohr G: Expression of indoleamine 2,3-dioxygenase in carcinoma of human endometrium and uterine cervix. Adv Exp Med Biol. 2003, 527: 91-95.CrossRefPubMed
34.
Lee SJ, Cho YS, Cho MC, Shim JH, Lee KA, Ko KK, Choe YK, Park SN, Hoshino T, Kim S, et al: Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-gamma production in human peripheral blood mononuclear and NK cells. J Immunol. 2001, 167 (1): 497-504.CrossRefPubMed
35.
Guess JC, McCance DJ: Decreased migration of Langerhans precursor-like cells in response to human keratinocytes expressing human papillomavirus type 16 E6/E7 is related to reduced macrophage inflammatory protein-3alpha production. J Virol. 2005, 79 (23): 14852-14862. 10.1128/JVI.79.23.14852-14862.2005.CrossRefPubMedPubMedCentral
36.
Jimenez-Flores R, Mendez-Cruz R, Ojeda-Ortiz J, Munoz-Molina R, Balderas-Carrillo O, de la Luz Diaz-Soberanes M, Lebecque S, Saeland S, Daneri-Navarro A, Garcia-Carranca A, et al: High-risk human papilloma virus infection decreases the frequency of dendritic Langerhans' cells in the human female genital tract. Immunology. 2006, 117 (2): 220-228. 10.1111/j.1365-2567.2005.02282.x.CrossRefPubMedPubMedCentral
37.
Albarran-Somoza B, Franco-Topete R, Delgado-Rizo V, Cerda-Camacho F, Acosta-Jimenez L, Lopez-Botet M, Daneri-Navarro A: CEACAM1 in cervical cancer and precursor lesions: association with human papillomavirus infection. J Histochem Cytochem. 2006, 54 (12): 1393-1399. 10.1369/jhc.6A6921.2006.CrossRefPubMedPubMedCentral
38.
Arnon TI, Markel G, Bar-Ilan A, Hanna J, Fima E, Benchetrit F, Galili R, Cerwenka A, Benharroch D, Sion-Vardy N, et al: Harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy. PLoS ONE. 2008, 3 (5): e2150-10.1371/journal.pone.0002150.CrossRefPubMedPubMedCentral
Metadata
Title
Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions
Authors
Trinidad Garcia-Iglesias
Alicia del Toro-Arreola
Benibelks Albarran-Somoza
Susana del Toro-Arreola
Pedro E Sanchez-Hernandez
Maria Guadalupe Ramirez-Dueñas
Luz Ma. Adriana Balderas-Peña
Alejandro Bravo-Cuellar
Pablo C Ortiz-Lazareno
Adrian Daneri-Navarro
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-9-186

Other articles of this Issue 1/2009

BMC Cancer 1/2009 Go to the issue

Research article

Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials

Research article

Overexpression of UbcH10 alternates the cell cycle profile and accelerate the tumor proliferation in colon cancer

Research article

Expression of BNIP3 in invasive breast cancer: correlations with the hypoxic response and clinicopathological features

Research article

Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers

Research article

Synthesis and expression of CDw75 antigen in human colorectal cancer

Research article

Validation of a prognostic scoring system for locally recurrent nasopharyngeal carcinoma treated by stereotactic radiosurgery
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits